Loading
Atara Biotherapeutics, Inc. Stock: price and insider trades · United States
1 insider bought €860k of shares over the last 90 days, the latest by Cherry Brian N, filed 04 Sept 2026.
Insider Decl.
868
Thresholds
n/a
Buy Volume
€2M
14 ops. · all time
Sell Volume
€47M
560 ops. · all time
Who traded when
BuySaleNguyen AnhCo13 sales
Yanina Grant-Huerta11 sales
Panacea Innovation Ltd2 buys1 sale
Henrich Jill2 sales
Hyllengren Eric J2 sales
Brian N. Cherry1 buy
Since the insiders bought
- -10.5%Entry US$10.23 · Close 20 Oct 2026 US$9.16
- -20.2%Entry US$11.76 · Close at T+365 US$9.38
- -0.2%Entry US$12.02 · Close at T+365 US$12.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,531 of 26,289 companies
78.1
score / 100
Value67
Quality90
FCF yld-54%
Earn yld35%
EV/EBITDA2.7x
ROE·
Gross mgn82%
Net mgn27%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$9.35
Analyst consensus
3 analysts1.67/5
US$10.00Target US$13.67(+46%)US$18.00
Income statement
RevenueUS$120.8M
Gross profitUS$99.6M82% margin
EBITDAUS$38.6M32% margin
Net incomeUS$32.7M-269.4% margin
Valuation
PER (forward)6.1x
Beta0.22
Balance sheet & cash
Market capUS$93.9M
Total debtUS$10.4M
Free Cash Flow-US$50.9M
Profitability & ownership
ROA-24.1%
% insiders16.8%
% institutions57.7%
Last declaration on 4 September 2026
Declarations868 total
104,166 shares@ US$9.601.14% mcap100.0% of flowCommon StockSEC:0000905148-26-004085:0
Canonical exit: 3 Dec 2026 (T+90)
5,062 shares@ US$8.360.048% mcap34.8% of flowCommon StockSEC144:0000905148-26-003961
5,062 shares@ US$8.07640.047% mcap33.7% of flowCommon StockSEC:0000905148-26-003960:0
60 sharesCommon StockSEC:0001104659-26-086733:1
195,211 sharesCommon StockSEC:0001104659-26-086733:0
24,000 sharesCommon StockSEC:0000905148-26-002951:0
12,000 sharesCommon StockSEC:0000905148-26-002921:0
12,000 sharesCommon StockSEC:0000905148-26-002919:0
12,000 sharesCommon StockSEC:0000905148-26-002920:0
5 shares@ US$5.230.0% of flowCommon StockSEC:0001193125-26-116060:1
259,163 shares0.0% of flowCommon StockSEC:0001193125-26-116060:0
81,100 shares0Common StockSEC:0000905148-26-001225:0
20,300 shares0Common StockSEC:0000905148-26-001224:0
1,603 shares@ US$5.0811.4% of flowCommon StockSEC:0000905148-26-001144:1
377 shares@ US$5.082.7% of flowCommon StockSEC:0000905148-26-001144:2
100 shares@ US$5.080.7% of flowCommon StockSEC:0000905148-26-001144:3
58 shares@ US$5.080.1% of flowCommon StockSEC:0000905148-26-001143:1
1,298 shares@ US$5.092.0% of flowCommon StockSEC:0000905148-26-001143:2
1,442 shares@ US$5.092.3% of flowCommon StockSEC:0000905148-26-001143:3
24 shares@ US$5.0770.8% of flowCommon StockSEC:0000905148-26-001144:0
198 shares@ US$5.0790.7% of flowCommon StockSEC:0000905148-26-001143:0
80,554 shares@ US$6.070742.2% of flowCommon StockSEC:0001193125-26-013358:0
1 shares@ US$14.030.0% of flowCommon StockSEC:0001193125-25-304018:1
48,737 shares0.0% of flowCommon StockSEC:0001193125-25-304018:0
85 shares@ US$13.191.6% of flowCommon StockSEC:0000905148-25-004140:1
25 of 868 declarations
About Atara Biotherapeutics, Inc.
Isaac E. Ciechanover, Chief Executive Officer of Atara Biotherapeutics, Inc., filed 269 of the company's 868 filings, including 250 sales and no purchase. Overall, sales dwarf purchases: 560 sales worth EUR 46,832,241 (median EUR 41,047) against 14 purchases worth EUR 2,413,562 (median EUR 52,511), so purchases are 2% of open-market trades, with 170 grants and 122 option exercises alongside.
The largest sales are by Joel S. Marcus, a director (EUR 1,983,817 on February 28, 2019), Mitchall G. Clark (EUR 1,096,863 on May 18, 2018) and Isaac E. Ciechanover (EUR 944,987 on July 9, 2018). On the purchase side, Brian N. Cherry, a director, bought EUR 860,494 on September 4, 2026, Panacea Innovation Ltd, a 10% owner, EUR 575,404 on August 15, 2025, and Kristin Yarema EUR 346,788 on June 14, 2021.
Read moreShow less
The US healthcare company, listed on Nasdaq and valued at USD 89,937,880, saw its filings peak in 2018 (248); there are 22 in 2026. Joe Newell has 73 filings (47 sales) and Christopher Haqq 53 (35). A 90-day result is stored for 12 purchases: median 18.6%, 92% positive (stored past results, not a forecast).
